These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22180491)

  • 21. Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA.
    Perez Castro S; Iñarrea Fernández A; Lamas González MJ; Sarán Diez MT; Cid Lama A; Alvarez Martín MJ; Pato Mosquera M; López-Miragaya I; Estévez N; Torres Piñón J; Oña Navarro M
    J Med Virol; 2013 Jun; 85(6):1063-8. PubMed ID: 23588733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increase in viral load, viral integration, and gain of telomerase genes during uterine cervical carcinogenesis can be simultaneously assessed by the HPV 16/18 MLPA-assay.
    Theelen W; Speel EJ; Herfs M; Reijans M; Simons G; Meulemans EV; Baldewijns MM; Ramaekers FC; Somja J; Delvenne P; Hopman AH
    Am J Pathol; 2010 Oct; 177(4):2022-33. PubMed ID: 20813962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of HPV 16 and 18 detection in serum of colposcopy clinic patients.
    Patel DA; Unger ER; Walline H; Opipari AW; Lee DR; Flowers LC; Ruffin MT
    J Clin Virol; 2011 Apr; 50(4):342-4. PubMed ID: 21306941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between the Abbott RealTime High Risk HPV assay and the Hybrid Capture 2 assay for detecting high-risk human papillomavirus DNA in cervical specimens.
    Kaliterna V; Židovec Lepej S; Vince A
    J Med Microbiol; 2009 Dec; 58(Pt 12):1662-1663. PubMed ID: 19661205
    [No Abstract]   [Full Text] [Related]  

  • 25. Diagnostic value of human papillomavirus (HPV) 16 and HPV18 viral loads for the detection of high-grade cervical intraepithelial neoplasia (CIN2+) in a cohort of African women living with HIV.
    Segondy M; Ngou J; Kelly H; Omar T; Goumbri-Lompo O; Doutre S; Mayaud P; Didelot MN
    J Clin Virol; 2018; 99-100():79-83. PubMed ID: 29353074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of cytology, HPV DNA testing and HPV 16/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening.
    Chatzistamatiou K; Moysiadis T; Moschaki V; Panteleris N; Agorastos T
    Gynecol Oncol; 2016 Jul; 142(1):120-127. PubMed ID: 27126005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The interplay of age stratification and HPV testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study.
    Stoler MH; Wright TC; Sharma A; Zhang G; Apple R; Wright TL; Behrens CM;
    Am J Clin Pathol; 2012 Feb; 137(2):295-303. PubMed ID: 22261457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How might HPV testing be integrated into cervical screening?
    Katki HA; Wentzensen N
    Lancet Oncol; 2012 Jan; 13(1):8-10. PubMed ID: 22177578
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.
    Huh WK; Ault KA; Chelmow D; Davey DD; Goulart RA; Garcia FAR; Kinney WK; Massad LS; Mayeaux EJ; Saslow D; Schiffman M; Wentzensen N; Lawson HW; Einstein MH
    Obstet Gynecol; 2015 Feb; 125(2):330-337. PubMed ID: 25569009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary HPV testing verification: A retrospective ad-hoc analysis of screening algorithms on women doubly tested for cytology and HPV.
    Tracht J; Wrenn A; Eltoum IE
    Diagn Cytopathol; 2017 Jul; 45(7):580-586. PubMed ID: 28436211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Enhanced molecular techniques for the diagnosis of human papillomavirus infections].
    Ursu RG; Onofriescu M; Nemescu D; Iancu LS
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1205-10. PubMed ID: 20191900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of cervical cancer in women with ASCUS in the Brazilian Unified National Health System: cost-effectiveness of the molecular biology method for HPV detection.
    Nomelini RS; Guimarães PD; Candido PA; Campos AC; Michelin MA; Murta EF
    Cad Saude Publica; 2012 Nov; 28(11):2043-52. PubMed ID: 23147946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventing human papillomavirus disease.
    Trimble CL
    J Clin Oncol; 2012 Sep; 30(25):3037-8. PubMed ID: 22851562
    [No Abstract]   [Full Text] [Related]  

  • 35. Human Papillomavirus Genotyping Testing Practice in 2014: Results of a College of American Pathologists National Survey.
    Zhao C; Crothers BA; Ghofrani M; Li Z; Souers RJ; Hussain M; Fan F; Ocal IT; Goodrich K; Shen R; Davey DD;
    Arch Pathol Lab Med; 2016 Dec; 140(12):1364-1370. PubMed ID: 27479334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical analysis of the infection with human papillomavirus in women].
    Li AX; Yin R; Zhong BY; Hao F
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):49-52. PubMed ID: 16816863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evaluation and budget impact analysis of cervical cancer screening using cobas 4800 HPV screening technology in the public sector of South Africa.
    Dreyer G; Maske C; Stander M
    PLoS One; 2019; 14(9):e0221495. PubMed ID: 31509545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost analysis of different cervical cancer screening strategies in Mexico.
    Beal CM; Salmerón J; Flores YN; Torres L; Granados-García V; Dugan E; Lazcano-Ponce E
    Salud Publica Mex; 2014; 56(5):429-501. PubMed ID: 25604287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.